Biosimilars in oncology: Current and future perspectives

Abstract

Cancer represents a significant, and growing, burden on healthcare systems by escalating cancer drug budgets. Available evidence indicates that biosimilars approved by regulatory authorities offer a safe and effective alternative to originator biological therapies. Therefore, greater adoption of biosimilars represents a key approach to reducing healthcare expenditure and improving patient access to important treatments.